PTGX Shares Plummet After FDA Approval Triggers $275M Milestone Payment

Protagonist Therapeutics (PTGX) saw its shares drop by 6.5% following the FDA approval of MIMRYLO, a treatment for erythrocytosis in adults with polycythemia vera. The approval triggered $275M in milestone payments to Protagonist Therapeutics.

The FDA's green light validates Protagonist's peptide platform and establishes the first approved hepcidin mimetic therapy in polycythemia vera, potentially reshaping treatment approaches for hematocrit control and phlebotomy reduction.

Investors now focus on visibility of MIMRYLO uptake and progress on Janssen-partnered JNJ-2113 program. However, concentration risk remains a concern with just a few partnered assets.